Linux Laboratories raises $70M from ChrysCapital and Tata Capital Healthcare Fund
Linux Laboratories will use the funding to support growth initiatives, including deepening its presence in core specialties, entering new therapeutic areas, and expanding its manufacturing facilities.
Chennai-based pharmaceutical company Linux Laboratories has secured $70 million in equity capital from two major investors - ChrysCapital and Tata Capital Healthcare Fund III. This financing, a mix of primary capital and secondary purchases, includes a significant minority stake acquisition by ChrysCapital and a full exit for Tata Capital Healthcare Fund II at an approximate 4x return.
Linux intends to leverage these funds for its growth trajectory, focusing on expanding its core specialties, venturing into adjacent therapeutic areas, acquiring more brands, and enhancing manufacturing and R&D capabilities. Established in 2007, Linux Laboratories is a specialty-focused domestic formulations platform boasting a portfolio of over 125 brands and 400 SKUs.
The company specializes in central nervous system (CNS) therapies, including treatments for epilepsy, neuropathic pain, depression, and autism, and has expanded into dermatology, cardio-diabetics, and nutraceuticals. Co-founder and Executive Director S Ananda Kumar stated, "Linux was built on the belief that a focused, science-led portfolio with affordability and access to quality healthcare can compete with the largest players in Indian pharma."
The company's growth strategy combines organic brand-building with inorganic methods, such as integrating and scaling Biomedica and Indiabulls Pharmaceuticals portfolios, as well as acquiring brands from Cipla and Dr. Reddy's Laboratories. Linux Laboratories also operates its own WHO-GMP certified manufacturing facility, supporting backward integration for the branded business while driving a growing contract development and manufacturing (CDMO) operation and export presence across various countries.
Kshitij Sheth, Managing Director at ChrysCapital Advisors, noted that this investment aligns with ChrysCapital's strategy of backing fast-growing domestic formulations companies with a focus on chronic therapies and led by visionary entrepreneurs. The India branded formulations market is currently attracting significant investor interest, fueled by the increasing prevalence of chronic and sub-chronic conditions and the rising share of specialty-led, prescriber-facing portfolios.
Avendus Capital served as the exclusive financial advisor to Linux Laboratories throughout the transaction.
Written by urgent.news from YourStory's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
